Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice

Molecular Genetics and Metabolism

Volumn 109, Issue 1, 2013, Pages 33-40

  Baldo, Guilherme ^a,b   Mayer, Fabiana Q ^a   Martinelli, Bárbara Z ^a,b   de Carvalho, Talita G ^a,b   Meyer, Fabiola S ^a   de Oliveira, Patrícia G ^a   Meurer, Luise ^a   Tavares, Ângela ^b   Matte, Ursula ^a,b   Giugliani, Roberto ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Blood brain barrier; Enzyme replacement therapy; Hurler Syndrome; Mucopolysaccharidosis I

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LARONIDASE; LEVO IDURONIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIRTH; BRAIN TISSUE; CONTROLLED STUDY; ENZYME REPLACEMENT; HEART FUNCTION; HURLER SYNDROME; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; FEMALE; GENETIC VECTORS; GLYCOSAMINOGLYCANS; HUMANS; IDURONIDASE; LYSOSOMES; MICE; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSIS I;

MUS;

EID: 84876092659     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.03.005     Document Type: Article

References (31)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452 2. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Giugliani R., Federhen A., Rojas M.V., Vieira T., Artigalas O., Pinto L.L., Azevedo A.C., Acosta A., Bonfim C., Lourenço C.M., Kim C.A., Horovitz D., Bonfim D., Marinho D., Palhares D., Santos E.S., Ribeiro E., Valadares E., Guarany F., de Luca G.R., Pimentel H., de Souza I.N., Correa J.S., Fraga J.C., Goes J.E., Cabral J.M., Simionato J., Llerena J.J., Jardim L., Giugliani L., da Silva L.C., Santos M.L., Moreira M.A., Kerstenetzky M., Ribeiro M., Ruas N., Barrios P., Aranda P., Honjo R., Boy R., Costa R., Souza C., Alcantara F.F., Avilla S.G., Fagondes S., Martins A.M. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet. Mol. Biol. 2010, 33:589-604.
3. Matte U., Lagranha V.L., de Carvalho T.G., Mayer F.Q., Giugliani R. Cell microencapsulation: a potential tool for the treatment of neuronopathic lysosomal storage diseases. J. Inherit. Metab. Dis. 2011, 34:983-990.
4. Dierenfeld A.D., McEntee M.F., Vogler C.A., Vite C.H., Chen A.H., Passage M., Le S., Shah S., Jens J.K., Snella E.M., Kline K.L., Parkes J.D., Ware W.A., Moran L.E., Fales-Williams A.J., Wengert J.A., Whitley R.D., Betts D.M., Boal A.M., Riedesel E.A., Gross W., Ellinwood N.M., Dickson P.I. Replacing the enzyme alpha-l-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci. Transl. Med. 2010, 2:60ra89.
5. Wraith J.E., Beck M., Lane R., Van der Ploeg A., Shapiro E., Xue Y., Kakkis E.D., Guffon N. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-l-iduronidase (laronidase). Pediatrics 2007, 120:e37-e46.
6. Gabrielli O., Clarke L.A., Bruni S., Coppa G.V. Enzyme replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 2009, 125:e183-e187.
7. Vogler C., Levy B., Galvin N.J., Thorpe C., Sands M.S., Barker J.E., Baty J., Birkenmeier E.H., Sly W.S. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr. Res. 1999, 45:838-844.
8. Baldo G., Matte U., Artigalas O., Schwartz I.V., Burin M.G., Ribeiro E., Horovitz D., Magalhaes T.P., Elleder M., Giugliani R. Placenta analysis of prenatally diagnosed patients reveals early GAG storage in mucopolysaccharidoses II and VI. Mol. Genet. Metab. 2011, 103:197-198.
9. Baldo G., Mayer F.Q., Martinelli B., Dilda A., Meyer F., Ponder K.P., Giugliani R., Matte U. Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice. Behav. Brain Res. 2012, 233:169-175.
10. Giugliani R., Rojas V.M., Martins A.M., Valadares E.R., Clarke J.T., Góes J.E., Kakkis E.D., Worden M.A., Sidman M., Cox G.F. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol. Genet. Metab. 2009, 96:13-19.
11. Baldo G., Quoos Mayer F., Burin M., Carrillo-Farga J., Matte U., Giugliani R. Recombinant encapsulated cells overexpressing alpha-l-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells. Cells Tissues Organs. 2012, 195:323-329.
12. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
13. Baldo G., Wu S., Howe R.A., Ramamoothy M., Knutsen RH R.H., Fang J., Mecham R.P., Liu Y., Wu X., Atkinson J.P., Ponder K.P. Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol. Genet. Metab. 2011, 104:608-619.
14. Tavares A.M., da Rosa Araújo A.S., Baldo G., Matte U., Khaper N., Belló-Klein A., Rohde L.E., Clausell N. Bone marrow derived cells decrease inflammation but not oxidative stress in an experimental model of acute myocardial infarction. Life Sci. 2010, 87:699-706.
15. Jones J.E., Mendes L., Rudd M.A., Russo G., Loscalzo J., Zhang Y.Y. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:364-371.
16. G. Baldo, D. Wozniak, K. Ohlemiller, Y. Zhang, R. Giugliani R, K.P. Ponder, Retroviral Vector-mediated Gene Therapy to Mucopolysaccharidosis I Mice Improves Sensorimotor Impairments and Other Behavior Deficits, J Inherit Metab Dis. in press.
17. Pan D., Sciascia A., Vorhees C.V., Williams M.T. Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome. Brain Res. 2008, 1188:241-253.
18. Baldo G., Mayer F.Q., Martinelli B., Meyer F., Burin M., Meurer L., Tavares A.M., Giugliani R., Matte U. Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-l-iduronidase partially corrects visceral pathology in Mucopolysaccharidosis type I mice. Cytotherapy 2012, 14:860-867.
19. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., Neufeld E.F. Enzyme replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 2001, 344:182-188.
20. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, doubleblinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J. Pediatr. 2004, 144:581-588.
21. O'Connor L.H., Erway L.C., Vogler C.A., Sly W.S., Nicholes A., Grubb J., Holmberg S.W., Levy B., Sands M.S. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J. Clin. Invest. 1998, 101:1394-1400.
22. Woloszynek J.C., Coleman T., Semenkovich C.F., Sands M.S. Lysosomal dysfunction results in altered energy balance. J. Biol. Chem. 2007, 282:35765-35771.
23. Braunlin E.A., Berry I.M., Whitley C.B. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am. J. Cardiol. 2006, 98:416-418.
24. Sifuentes M., Doroshow R., Hoft R., Mason G., Walot I., Diament M., Okazaki S., Huff K., Cox G.F., Swiedler S.J., Kakkis E.D. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6years. Mol. Genet. Metab. 2007, 90:171-180.
25. Watanabe N., Anagnostopoulos P.V., Azakie A. Aortic stenosis in a patient with Hurler's syndrome after bone marrow transplantation. Cardiol. Young 2011, 21:349-350.
26. Ma X., Tittiger M., Knutsen R.H., Kovacs A., Schaller R., Mecham R.P., Ponder K.P. Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol. Genet. Metab. 2008, 94:298-304.
27. Kakkis E.D., Schuchman E., He X., Wan Q., Kania S., Wiemelt S., Hasson C.W., O'Malley T., Weil M.A., Aguirre G.A., Brown D.E., Haskins M.E. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol. Genet. Metab. 2001, 72:199-208.
28. Wang R.Y., Cambray-Forker E.J., Ohanian K., Karlin D.S., Covault K.K., Schwartz P.H., Abdenur J.E. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Mol. Genet. Metab. 2009, 98:406-411.
29. Tylki-Szymanska A., Marucha J., Jurecka A., Syczewska M., Czartoryska B. Efficacy of recombinant human alpha-l-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J. Inherit. Metab. Dis. 2010, 33:151-157.
30. Kakavanos R., Turner C.T., Hopwood J.J., Kakkis E.D., Brooks D.A. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003, 361:1608-1613.
31. Ponder K.P. Immune response hinders therapy for lysosomal storage diseases. J. Clin. Invest. 2008, 118:2686-2689.